home / stock / qlgn / qlgn news

QLGN News and Press, Qualigen Therapeutics Inc. From 01/10/23

Stock Information
Company Name: Qualigen Therapeutics Inc.
Stock Symbol: QLGN
Market: NASDAQ
Website: qualigeninc.com
Menu
QLGN QLGN Quote QLGN Short QLGN News QLGN Articles QLGN Message Board
Get QLGN Alerts

News, Short Squeeze, Breakout and More Instantly...
QLGN - Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
QLGN - Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...

QLGN - Qualigen Therapeutics regains compliance with Nasdaq minimum bid price rule

Qualigen Therapeutics ( NASDAQ: QLGN ) has received Nasdaq notice, informing the company that it has regained compliance minimum bid price requirement and the matter is now closed. The closing bid price of the company’s common stock having been at least $1.00 per share for ...

QLGN - Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
QLGN - Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...

QLGN - Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Action to comply with continued listing requirements for Nasdaq Capital Market CARLSBAD, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adu...

QLGN - Qualigen Therapeutics GAAP EPS of -$0.10 beats by $0.06, revenue of $1.44M misses by $0.18M

Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q3 GAAP EPS of -$0.10 beats by $0.06 . Revenue of $1.44M (+24.1% Y/Y) misses by $0.18M . For further details see: Qualigen Therapeutics GAAP EPS of -$0.10 beats by $0.06, revenue of $1.44M misses by $0...
QLGN - Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Q3 2022 FastPack ® sales increased approximately 25% year-over-year Company continues to execute on and advance core therapeutic programs CARLSBAD, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutic...

QLGN - Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Fou r th RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing t...

QLGN - Qualigen Therapeutics to Present at LD Micro Main Event XV

CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...
Previous 10 Next 10